Core business growth hits the highest in over a decade! Gilead (GILD.US) Q3 brings both good and bad news: raises full-year sales guidance but Biktarvy faces a 38% price cut pressure from US Medicare

Jitotong Finance APP has learned that US biopharmaceutical giant Gilead Sciences (GILD.US) released its Q3 2026 financial report on Thursday, October 29, local time. Driven by double-digit growth in its flagship HIV medication portfolio, the company’s product sales for the quarter increased by 13% year-on-year to $8.3 billion, surpassing market expectations. Excluding the COVID-19 drug Veklury (Remdesivir), "core business" sales rose 16% year-on-year to $8.2 billion, marking the fastest year-on-year growth in core business in over a decade. Based on this strong performance, the company has once again raised its full-year sales guidance.